<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Patient survival after kidney transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Patient survival after kidney transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Patient survival after kidney transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane C Tan, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney transplantation is the treatment of choice for selected patients with end-stage kidney disease (ESKD) [<a href="#rid1">1</a>]. A successful kidney transplant improves the quality of life and reduces the mortality risk for most patients when compared with maintenance dialysis [<a href="#rid2">2-4</a>]. Survival rates posttransplantation are similar for both patients on hemodialysis and those on peritoneal dialysis [<a href="#rid5">5</a>].</p><p>The following discussion will review the data relating to patient survival in adult patients undergoing kidney transplantation. Patient survival in children undergoing kidney transplantation and the determinants of short-term and long-term graft survival are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes", section on 'Patient survival'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure"</a>.)</p><p></p><p class="headingAnchor" id="H1608007788"><span class="h1">PATIENT SURVIVAL IN ADULT KIDNEY TRANSPLANT RECIPIENTS</span></p><p class="headingAnchor" id="H3352665279"><span class="h2">Short- and long-term survival rates</span><span class="headingEndMark"> — </span>Both short- and long-term patient and graft survival rates among adult kidney transplant recipients have improved over time  (<a class="graphic graphic_figure graphicRef141273" href="/z/d/graphic/141273.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef141274" href="/z/d/graphic/141274.html" rel="external">figure 2</a>) [<a href="#rid6">6,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of data from the Scientific Registry of Transplant Recipients (SRTR) from 1996 to 2019 reported the following findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For deceased-donor kidney transplants, 10-year patient survival increased from 60.5 percent between 1996 and 1999 to 66.9 percent between 2008 and 2011. Similarly, 10-year overall graft survival increased from 42.3 percent between 1996 and 1999 to 53.6 percent between 2008 and 2011.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For living-donor kidney transplants, 10-year patient survival increased from 75.3 percent between 1996 and 1999 to 81.3 percent between 2008 and 2011. Similarly, 10-year overall graft survival increased from 53.6 percent between 1996 and 1999 to 69.6 percent between 2008 and 2011.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>These improvements have occurred despite unfavorable changes in donor and recipient characteristics, such as increases in recipient and donor age, body mass index, prevalence of diabetes mellitus in both recipient and donors, duration of time on dialysis, and degree of HLA presensitization. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate, large SRTR analysis of 331,216 adult solitary kidney transplants from 1995 to 2017, median survival of deceased-donor kidney transplant recipients increased from 8.2 years between 1995 and 1999 to an estimated 11.7 years between 2014 and 2017 [<a href="#rid6">6</a>]. Similarly, median survival for living-donor kidney transplant recipients increased from 12.1 years between 1995 and 1999 to an estimated 19.2 years between 2014 and 2017. The overall (deceased and living donor) adjusted hazard ratio of graft failure decreased from 0.89 (95% CI 0.88-0.91) between 2000 and 2004 to 0.46 (95% CI 0.45-0.47) between 2014 and 2017, with 1995 to 1999 as the reference.</p><p></p><p>These improvements in long-term outcomes have been attributed to multiple factors, including lower rates of acute rejection, better pretransplant crossmatch techniques, judicious use of kidney paired donation (KPD) transplants for patients with incompatible living donors, surveillance for viral infections, and effective antiviral prophylaxis [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H1392616954"><span class="h2">Survival compared with dialysis</span><span class="headingEndMark"> — </span>Given that many patients on dialysis are inappropriate candidates for kidney transplantation because of severe multiorgan disease and/or multimorbidity associated with age, the assessment of relative mortality is best performed by comparing the survival rates between patients accepted for kidney transplantation who have undergone transplant surgery with those accepted for transplantation but who have not yet received a kidney allograft (ie, patients on dialysis who are on the transplant waiting list).</p><p>Several studies using these two comparative groups have found that patient survival is overall <strong>better</strong> with kidney transplantation than with dialysis [<a href="#rid8">8-10</a>]. A 2022 systematic review of 48 observational studies (1,245,850 patients) comparing all-cause mortality between kidney transplantation and dialysis in waitlisted patients reported the following findings [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The mortality risk in transplant recipients was higher than in waitlisted patients on dialysis immediately after transplantation (hazard ratio [HR] range 1.3 to 17.7 at 0 to 30 days; 1.5 to 4.8 at 0 to 3 months), which was attributable to perioperative and postoperative risk factors. However, this increased risk was eventually offset, and by one year, the mortality risk was lower in transplant recipients (HR range 0.19 to 0.49).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improved survival with transplantation was observed among all adults ≥18 years old, older adults (variably defined as ≥60, ≥65, or ≥70 years old), and patients with obesity, diabetes, systemic sclerosis, peripheral artery disease, or hepatitis C virus as comorbidities. A greater survival benefit was observed with living-donor versus deceased-donor transplantation, standard criteria donors versus expanded criteria donors, and hepatitic C virus seronegative versus seropositive donor transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 18 of the studies, kidney transplantation was associated with a 55 percent lower risk of long-term mortality (HR 0.45, 95% CI 0.39-0.54). However, the study authors found significant heterogeneity between studies that may limit external validity of this finding for certain patient cohorts such as older transplant candidates.</p><p></p><p>Repeat kidney transplantation after a failed primary transplant also may confer a survival benefit [<a href="#rid11">11,12</a>]. In a large series of over 19,000 kidney transplant recipients with primary allograft failure, repeat kidney transplantation was associated with a 45 and 23 percent reduction in mortality at five years for patients with type 1 diabetes mellitus and those without diabetes, respectively, compared with those remaining on the waiting list [<a href="#rid11">11</a>]. Since patients with a failed primary transplant may comprise nearly 30 percent of current waiting lists, these added survival benefits with repeat transplantation have a significant impact upon overall mortality from ESKD.</p><p>However, these data need to be interpreted with caution. Although the authors of the last study attempted to utilize a "control" group (ie, those listed for transplantation who did not actually receive a transplant), selection bias almost certainly played some role in these results. Patients listed for transplantation may not have been transplanted, due to the development of intercurrent disease that led to death. This is a limitation common to all studies that rely upon the review of registry data.</p><p>The reduction in mortality among transplant recipients, compared with patients on dialysis, is due in part to a decrease in cardiovascular events, especially among patients with diabetes. Transplantation reduces the risk of fatal and nonfatal cardiovascular complications, compared with long-term dialysis, among patients selected to be suitable transplant candidates [<a href="#rid13">13-17</a>].</p><p class="headingAnchor" id="H3092492063"><span class="h2">Survival compared with general population</span><span class="headingEndMark"> — </span>Although transplantation confers the highest survival benefit among all of the different kidney replacement therapies, kidney allograft recipients still have a high mortality rate compared with population controls. In one study, for example, the mortality of recipients of first kidney transplants was 14 times higher than the age-matched population without kidney failure during the first year after transplantation and was four times higher after this period [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H3484563694"><span class="h1">FACTORS THAT AFFECT PATIENT SURVIVAL</span><span class="headingEndMark"> — </span>Patient survival after kidney transplantation varies based upon the source of the allograft, patient age, and the presence and degree of severity of comorbid conditions. Other possible contributing factors include sex, race, and level of cumulative immunosuppression.</p><p class="headingAnchor" id="H3184157911"><span class="h2">Allograft source</span><span class="headingEndMark"> — </span>The survival of patients receiving an allograft from a living donor is superior to those who receive a kidney from a deceased donor, including both nonexpanded-criteria and expanded-criteria donors [<a href="#rid19">19,20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For recipients of living-donor kidney transplants, patient survival rate at five years posttransplantation is 91 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For recipients of deceased, standard criteria donor transplants, the survival rate is 84 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For recipients of deceased, kidney donor profile index (KDPI) &gt;85 donor transplants, the survival rate is 70 percent.</p><p></p><p>The KDPI &gt;85 percent has replaced the expanded-donor-criteria terminology based on the observation that many factors impact organ quality and outcomes (see  <a class="medical medical_review" href="/z/d/html/7337.html" rel="external">"Kidney transplantation in adults: Organ sharing"</a>). The outcomes of recipients who receive such kidneys with higher KDPIs decline slowly until KDPI exceeds 85 percent. Kidneys with a KDPI &gt;85 percent approximate the prior expanded-donor-criteria definitions, if imperfectly. The outcomes of such transplants were evaluated in a study that compared the survival of candidates older than 60 years who either received a KDPI &gt;85 percent allograft or remained on dialysis [<a href="#rid21">21</a>]. Mortality after the first posttransplant year was markedly reduced in those who received such higher-risk kidneys (either preemptively before the need for dialysis or nonpreemptively after dialysis initiation) compared with those who were listed but never transplanted.</p><p class="headingAnchor" id="H113173211"><span class="h2">Recipient and deceased-donor age</span><span class="headingEndMark"> — </span>Patients of increasing age who undergo kidney transplantation have a higher mortality rate than younger recipients  (<a class="graphic graphic_figure graphicRef141270" href="/z/d/graphic/141270.html" rel="external">figure 3</a>) [<a href="#rid22">22</a>]. In the 2021 Scientific Registry of Transplant Recipients (SRTR) report on the state of transplantation, for example, the one- and five-year survival rates for children age 6 to 11 years who received a deceased-donor kidney were 99 and 97 percent, respectively [<a href="#rid23">23</a>]. </p><p>Although lower than in children, survival of the older transplant recipient is currently excellent. With present therapy, the survival at one and five years of patients &gt;65 years of age is approximately 93 and 73 percent, respectively, for deceased-donor transplants and 98 and 84 percent, respectively, for living-donor transplants [<a href="#rid23">23</a>]. As a result, the older patient on dialysis should not be excluded as a possible transplant recipient based upon age alone. (See  <a class="medical medical_review" href="/z/d/html/7312.html" rel="external">"Kidney transplantation and the older adult patient"</a>.)</p><p class="headingAnchor" id="H533857975"><span class="h2">Comorbid conditions</span><span class="headingEndMark"> — </span>The presence of systemic disorders, particularly vascular disease, is associated with poorer long-term patient survival after kidney transplantation. In a single-center study, high comorbidity (as assessed by the Charlson comorbidity index) correlated with an increased risk of death in both the perioperative period (hazard ratio [HR] 3.20) and more than three months after transplantation [<a href="#rid24">24</a>].</p><p>Patients with disease primarily affecting the kidney, such as autosomal dominant polycystic kidney disease and glomerulonephritis, have better long-term survival than those with systemic disorders, such as hypertension and diabetes. Obesity is also associated with an increased risk of death [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H3226091277"><span class="h3">Cardiovascular disease</span><span class="headingEndMark"> — </span>Fifty to 60 percent of deaths among kidney transplant recipients are directly attributable to cardiovascular disease, which has a reported incidence of approximately 1 per 100 person-years at risk [<a href="#rid27">27,28</a>]. Death from cardiovascular disease is also the most common cause of graft loss, accounting for 30 percent of graft loss from death overall, with the greatest rates early after transplant [<a href="#rid29">29</a>]. However, one must keep in mind that most of the deaths attributable to cardiovascular disease are among those with diabetes, whereas infection, malignancy, and others are more commonly the cause of death among those without diabetes [<a href="#rid17">17</a>].</p><p>Since cardiovascular disease is the leading cause of death for adult kidney allograft recipients, it is important to evaluate the extent and severity of coronary disease prior to transplantation (see  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"</a>). Nearly one-third of all such deaths are due to acute myocardial infarction (MI), with patients with diabetes having the worst survival post-MI [<a href="#rid13">13,30</a>].</p><p>Among those who require intervention for coronary artery disease after transplantation, myocardial revascularization is associated with acceptable immediate and long-term survival and similar outcomes with percutaneous and surgical techniques:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of kidney transplant recipients who underwent a first coronary revascularization procedure from 1995 to 1999, in-hospital mortality was 2.3, 4,3, 9.4, and 5 percent for 909 stent patients, 652 percutaneous coronary angioplasty (PTCA) patients, 288 coronary artery bypass graft (CABG; without internal mammary grafting), and 812 CABG (with internal mammary grafting) patients, respectively [<a href="#rid31">31</a>]. At two years, all-cause survival was 83, 82, 74, and 83 percent for the stent, PTCA, CABG (without internal mammary grafting), and CABG (with internal mammary grafting) groups, respectively.</p><p></p><p class="bulletIndent1">Compared with PTCA, the relative risk of death or acute MI for stent, CABG (without internal mammary grafting), and CABG (with internal mammary grafting) was 0.90, 0.80, and 0.57 (95% CI 0.42-0.76), respectively. Thus, similar long-term survival has been reported with surgical and percutaneous techniques, with the best survival being observed with CABG with an internal mammary graft. (See  <a class="medical medical_review" href="/z/d/html/1554.html" rel="external">"Coronary artery bypass graft surgery: Graft choices"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study of nearly 3000 kidney transplant recipients at one institution, survival of the 83 who required either bypass surgery or angioplasty was 89, 77, and 65 percent at one, three, and five years postprocedure, respectively [<a href="#rid32">32</a>].</p><p></p><p>De novo heart failure, a common condition among patients after kidney transplantation, is associated with poor survival. Based upon registry data from the United States Renal Data System (USRDS), the onset of heart failure increased the risk of death (adjusted HR [aHR] 2.6, 95% CI 2.4-2.9) and death-censored graft failure (aHR 2.7, 95% CI 2.4-3.0) [<a href="#rid14">14</a>]. Similarly, the development of atrial fibrillation increases the risk of death (aHR 3.2, 95% CI 2.9-3.6) and death-censored graft failure (aHR 1.9, 95% CI 1.6-2.3) [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H4177355057"><span class="h3">Diabetes mellitus</span><span class="headingEndMark"> — </span>Survival of patients with diabetes after kidney transplantation (75 to 80 percent at five years) is lower than that reported in patients without diabetes [<a href="#rid34">34,35</a>]. However, these results, due largely to extrarenal vascular disease, are still markedly better than those seen with dialysis, where the five-year patient survival rate is approximately 30 percent. (See  <a class="medical medical_review" href="/z/d/html/7349.html" rel="external">"Kidney transplantation in diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H2304581356"><span class="h2">Overall immunosuppression</span><span class="headingEndMark"> — </span>The level of overall immunosuppression used for induction therapy, maintenance therapy, and the treatment of acute rejection episodes is a major risk factor for posttransplant infection, rather than the use of a specific immunosuppressive agent. Since infections are the leading cause of mortality in the early posttransplant period, infection and allograft dysfunction caused by rejection are closely interrelated through the use of immunosuppressive therapy [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H350231363"><span class="h2">Allograft function</span><span class="headingEndMark"> — </span>Several studies have shown that graft function is also associated with patient survival [<a href="#rid38">38-41</a>]. In a retrospective study of nearly 600 recipients of first deceased-donor allografts, significantly increased mortality was observed in patients with a primary nonfunctioning graft (ie, a graft that never functions) compared with those with less severe graft dysfunction (45 versus 20 percent at six years) [<a href="#rid38">38</a>]. The predominant cause of death was cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>.)</p><p>Patient survival is high among those with persistent, long-term graft function. In one survey of over 86,000 patients, of whom nearly 18,500 died over a 10-year period, survival at 1, 5, and 10 years was 97, 91, and 86 percent, respectively, among those with continued kidney allograft function [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H2134897256"><span class="h1">CAUSES OF DEATH</span><span class="headingEndMark"> — </span>Atherosclerotic cardiovascular disease continues to be the overall major cause of death after kidney transplantation, especially in recipients with diabetes, whereas infection and malignancy are the major causes of death among recipients without diabetes [<a href="#rid17">17</a>]. The causes of death among transplant recipients have changed over time and vary with age [<a href="#rid42">42,43</a>]. In a single-center study, for example, cardiac disease, cancer, and stroke as causes of death increased from 9.6, 1.2, and 2.4 percent, respectively, for the period 1970 to 1979 to 30.3, 13.2, and 8 percent for 1990 to 1999 [<a href="#rid43">43</a>].</p><p>In addition, death from cardiovascular disease is much less common among younger than older individuals [<a href="#rid44">44</a>]. Among prevalent transplant patients from 1994 to 1996, the following were the percentage of deaths due to the most significant life-threatening disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>All cardiac causes accounted for 18, 33, and 37 percent of deaths for those aged 0 to 19, 20 to 44, and 45 to 64, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection accounted for 25, 17, and 19 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy accounted for 16, 8, and 11 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other known causes accounted for 41, 24, and 18 percent, respectively.</p><p></p><p class="headingAnchor" id="H3459577654"><span class="h1">ESTIMATED POSTTRANSPLANT SURVIVAL</span><span class="headingEndMark"> — </span>When a candidate is offered a kidney for transplant, available information about the candidate at the time of the organ offer will be used by the United Network for Organ Sharing (UNOS) to determine the candidate's estimated posttransplant survival (EPTS) score. This is for the purpose of allocating the organ. Patients with the most favorable EPTS score are allocated the best quality allografts that will provide the optimal long-term outcomes. The calculation for the EPTS score is based on four factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Candidate age</p><p class="bulletIndent1"><span class="glyph">●</span>Length of time on dialysis</p><p class="bulletIndent1"><span class="glyph">●</span>Any prior organ transplant</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes status</p><p></p><p>The 20 percent of adult candidates with the lowest EPTS score are eligible to receive priority for kidneys from the highest-quality donors (as defined by Kidney Donor Profile Index [KDPI] scores in the top 20 percent) [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/7337.html" rel="external">"Kidney transplantation in adults: Organ sharing", section on 'National deceased-donor kidney allocation policy'</a>.)</p><p class="headingAnchor" id="H71396327"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16440.html" rel="external">"Patient education: Kidney transplant (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16442.html" rel="external">"Patient education: Planning for a kidney transplant (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2721697108"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Kidney transplantation is the treatment of choice for selected patients with end-stage kidney disease (ESKD). A successful kidney transplant improves the quality of life and reduces the mortality risk for most patients when compared with maintenance dialysis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient survival in adult kidney transplant recipients</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Short- and long-term survival rates </strong>– Both short- and long-term patient and graft survival rates among adult kidney transplant recipients have improved over time  (<a class="graphic graphic_figure graphicRef141273" href="/z/d/graphic/141273.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef141274" href="/z/d/graphic/141274.html" rel="external">figure 2</a>). These improvements in long-term outcomes have been attributed to multiple factors, including lower rates of acute rejection, better pretransplant crossmatch techniques, judicious use of kidney paired donation (KPD) transplants for patients with incompatible living donors, surveillance for viral infections, and effective antiviral prophylaxis. (See <a class="local">'Short- and long-term survival rates'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Survival compared with dialysis </strong>– Studies comparing patients accepted for kidney transplantation who have undergone transplant surgery with those accepted for transplantation but who have not yet received a kidney allograft (ie, patients on dialysis who are on the transplant waiting list) have found that patient survival is overall <strong>better</strong> with kidney transplantation than with dialysis. (See <a class="local">'Survival compared with dialysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Survival compared with general population </strong>– Although transplantation confers the highest survival benefit among all of the different kidney replacement therapies, kidney allograft recipients still have a high mortality rate compared with population controls. (See <a class="local">'Survival compared with general population'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that affect survival </strong>– Posttransplantation survival rates vary based upon the source of the allograft, recipient and donor age, and the presence and severity of comorbid conditions. Other factors that may contribute to survival rates include sex, race, and degree of immunosuppression. (See <a class="local">'Factors that affect patient survival'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of death </strong>– Atherosclerotic cardiovascular disease is the major cause of death after kidney transplantation, especially in recipients with diabetes, whereas infection and malignancy are the major causes of death among recipients without diabetes. The causes of death among transplant recipients have changed over time and vary with age. (See <a class="local">'Causes of death'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331:365.</a></li><li><a class="nounderline abstract_t">Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9:2135.</a></li><li><a class="nounderline abstract_t">Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270:1339.</a></li><li><a class="nounderline abstract_t">Ojo AO, Port FK, Wolfe RA, et al. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994; 24:59.</a></li><li><a class="nounderline abstract_t">Snyder JJ, Kasiske BL, Gilbertson DT, Collins AJ. A comparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int 2002; 62:1423.</a></li><li><a class="nounderline abstract_t">Poggio ED, Augustine JJ, Arrigain S, et al. Long-term kidney transplant graft survival-Making progress when most needed. Am J Transplant 2021; 21:2824.</a></li><li><a class="nounderline abstract_t">Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl J Med 2021; 385:729.</a></li><li><a class="nounderline abstract_t">Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725.</a></li><li><a class="nounderline abstract_t">Chaudhry D, Chaudhry A, Peracha J, Sharif A. Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis. BMJ 2022; 376:e068769.</a></li><li><a class="nounderline abstract_t">Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011; 11:2093.</a></li><li><a class="nounderline abstract_t">Ojo A, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation 1998; 66:1651.</a></li><li><a class="nounderline abstract_t">Rao PS, Schaubel DE, Wei G, Fenton SS. Evaluating the survival benefit of kidney retransplantation. Transplantation 2006; 82:669.</a></li><li><a class="nounderline abstract_t">Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.</a></li><li><a class="nounderline abstract_t">Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis 2005; 46:720.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4:1662.</a></li><li><a class="nounderline abstract_t">Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3:1090.</a></li><li><a class="nounderline abstract_t">Cosio FG, Hickson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 2008; 8:593.</a></li><li><a class="nounderline abstract_t">Arend SM, Mallat MJ, Westendorp RJ, et al. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997; 12:1672.</a></li><li><a class="nounderline abstract_t">Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 2005; 5:843.</a></li><li><a class="nounderline abstract_t">McCullough KP, Keith DS, Meyer KH, et al. Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease. Am J Transplant 2009; 9:894.</a></li><li><a class="nounderline abstract_t">Jay CL, Washburn K, Dean PG, et al. Survival Benefit in Older Patients Associated With Earlier Transplant With High KDPI Kidneys. Transplantation 2017; 101:867.</a></li><li><a class="nounderline abstract_t">Becker BN, Becker YT, Pintar TJ, et al. Using renal transplantation to evaluate a simple approach for predicting the impact of end-stage renal disease therapies on patient survival: observed/expected life span. Am J Kidney Dis 2000; 35:653.</a></li><li class="breakAll">OPTN/SRTR 2021 Annual Data Report: Kidney. Scientific Registry of Transplant Recipients. Available at: https://srtr.transplant.hrsa.gov/annual_reports/2021/Kidney.aspx#fig:KItx-adult-pat-surv-DD-5y-age (Accessed on April 17, 2023).</li><li><a class="nounderline abstract_t">Wu C, Evans I, Joseph R, et al. Comorbid conditions in kidney transplantation: association with graft and patient survival. J Am Soc Nephrol 2005; 16:3437.</a></li><li><a class="nounderline abstract_t">Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004; 65:597.</a></li><li><a class="nounderline abstract_t">Glanton CW, Kao TC, Cruess D, et al. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int 2003; 63:647.</a></li><li><a class="nounderline abstract_t">Yeo FE, Villines TC, Bucci JR, et al. Cardiovascular risk in stage 4 and 5 nephropathy. Adv Chronic Kidney Dis 2004; 11:116.</a></li><li><a class="nounderline abstract_t">Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82:603.</a></li><li class="breakAll">US Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD 2008.</li><li><a class="nounderline abstract_t">Herzog CA, Ma JZ, Collins AJ. Long-term survival of renal transplant recipients in the United States after acute myocardial infarction. Am J Kidney Dis 2000; 36:145.</a></li><li><a class="nounderline abstract_t">Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. Circulation 2004; 109:2866.</a></li><li><a class="nounderline abstract_t">Ferguson ER, Hudson SL, Diethelm AG, et al. Outcome after myocardial revascularization and renal transplantation: a 25-year single-institution experience. Ann Surg 1999; 230:232.</a></li><li><a class="nounderline abstract_t">Lentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol 2006; 1:288.</a></li><li><a class="nounderline abstract_t">Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004; 15 Suppl 1:S25.</a></li><li><a class="nounderline abstract_t">Lufft V, Dannenberg B, Schlitt HJ, et al. Cardiovascular morbidity and mortality in patients with diabetes mellitus type I after kidney transplantation: a case-control study. Clin Nephrol 2004; 61:238.</a></li><li><a class="nounderline abstract_t">Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993; 44:221.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13:769.</a></li><li><a class="nounderline abstract_t">Woo YM, Jardine AG, Clark AF, et al. Early graft function and patient survival following cadaveric renal transplantation. Kidney Int 1999; 55:692.</a></li><li><a class="nounderline abstract_t">Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57:307.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Israni AK, Snyder JJ, et al. The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis 2011; 57:466.</a></li><li><a class="nounderline abstract_t">Clayton PA, Lim WH, Wong G, Chadban SJ. Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants. J Am Soc Nephrol 2016; 27:3440.</a></li><li class="breakAll">U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003.</li><li><a class="nounderline abstract_t">Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73:1923.</a></li><li><a class="nounderline abstract_t">Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16:1545.</a></li><li class="breakAll">UNOS regulations. http://optn.transplant.hrsa.gov/SharedContentDocuments/KidneyConceptDocument.PDF (Accessed on November 12, 2013).</li></ol></div><div id="topicVersionRevision">Topic 7347 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832839" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808102" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8360969" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023825" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12234315" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A comparison of transplant outcomes in peritoneal and hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346917" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term kidney transplant graft survival-Making progress when most needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34407344" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-Term Survival after Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10580071" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35232772" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883901" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9884254" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16969291" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evaluating the survival benefit of kidney retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15615820" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence and predictors of myocardial infarction after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183428" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367222" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385393" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294155" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269647" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Patient survival after renal transplantation; more than 25 years follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15760412" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Trends and results for organ donation and transplantation in the United States, 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19341414" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27495758" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Survival Benefit in Older Patients Associated With Earlier Transplant With High KDPI Kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10739786" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Using renal transplantation to evaluate a simple approach for predicting the impact of end-stage renal disease therapies on patient survival: observed/expected life span.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10739786" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Using renal transplantation to evaluate a simple approach for predicting the impact of end-stage renal disease therapies on patient survival: observed/expected life span.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16176999" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comorbid conditions in kidney transplantation: association with graft and patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717930" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631130" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15216484" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cardiovascular risk in stage 4 and 5 nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16969281" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cardiovascular complications after renal transplantation and their prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16969281" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cardiovascular complications after renal transplantation and their prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10873884" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term survival of renal transplant recipients in the United States after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159290" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10450738" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Outcome after myocardial revascularization and renal transplantation: a 25-year single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699219" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684667" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Renal replacement therapy in patients with diabetes and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125029" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cardiovascular morbidity and mortality in patients with diabetes mellitus type I after kidney transplantation: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8394951" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Infectious disease complications of renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856783" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9987094" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Early graft function and patient survival following cadaveric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620213" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term survival in renal transplant recipients with graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21257243" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The relationship between kidney function and long-term graft survival after kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27059513" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27059513" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131689" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The changing causes of graft loss and death after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477152" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Causes of death after renal transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
